Perspective Therapeutics, Inc.
CATX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $205,516 | $220,721 | $135,617 | $169,658 |
| - Cash | $61,580 | $9,238 | $20,993 | $60,354 |
| + Debt | $4,062 | $2,551 | $0 | $652 |
| Enterprise Value | $147,998 | $214,034 | $114,624 | $109,956 |
| Revenue | $0 | $1,434 | $7,104 | $10,795 |
| % Growth | -100% | -79.8% | -34.2% | – |
| Gross Profit | $0 | $1,434 | $1,634 | $4,616 |
| % Margin | – | 100% | 23% | 42.8% |
| EBITDA | $10,459 | -$39,960 | -$14,838 | -$7,391 |
| % Margin | – | -2,786.6% | -208.9% | -68.5% |
| Net Income | -$79,279 | -$46,508 | -$14,670 | -$7,153 |
| % Margin | – | -3,243.2% | -206.5% | -66.3% |
| EPS Diluted | -1.23 | -0.85 | -0.27 | -0.13 |
| % Growth | -44.7% | -214.8% | -107.7% | – |
| Operating Cash Flow | -$18,294 | -$36,913 | -$12,172 | -$7,710 |
| Capital Expenditures | -$54,414 | -$1,072 | -$302 | -$266 |
| Free Cash Flow | -$72,708 | -$37,985 | -$12,474 | -$7,976 |